anonymous
Guest
anonymous
Guest
As a long-timer at DEX I can already see that with the many big Pharma management and rep hires from Novo, our time as a medical device company is transitioning to a metric driven drug rep calls per day model.
Not hating on the new folks and the expansion but I would have thought folks would not want to have that culture when they came aboard. Interesting times ahead.
Not hating on the new folks and the expansion but I would have thought folks would not want to have that culture when they came aboard. Interesting times ahead.